Sucampo and Takeda Initiate Global Pivotal Phase 3 Program of Lubiprostone in Pediatric Functional Constipation
17 déc. 2013 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md. and DEERFIELD, Ill., Dec. 17, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") and its development and commercialization partner Takeda Pharmaceuticals...
Sucampo Announces Presentation of Results on Lubiprostone in Pediatric Functional Constipation at NASPGHAN 2013
10 oct. 2013 20h00 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Oct. 10, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") today announced the presentation of results from a Phase 3, open-label safety and efficacy...